Alnylam Pharmaceuticals, Inc.
About Alnylam Pharmaceuticals
Alnylam is leading the translation of RNA interference (RNAi) into a new class of medicines for rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics are a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is headquartered in Cambridge, MA. For more information visit www.alnylam.com.